Europe has begun preparing for a hypothetical pandemic involving avian influenza viruses.After the impact of COVID-19 in recent years, the European Medicines Agency (EMA) has bird flu vaccine.
In fact, there are two preliminary vaccines against this pathogen; Influenza A virus H5N1 subtype. The first recipe was based on a virus that spread in turkeys in 2005. The first dose is a cellular epidemic (zoonotic influenza vaccine). It will be used for immunization during animal influenza outbreaks.
They are formed from two proteins on the surface of the virus, hemagglutinin and neuraminidase, and trigger the immune system’s response to the vaccination dose.On the other hand, there are second formula, pandemic preparedness.its about incelipan (pandemic influenza vaccine). Unlike the first one, it would be used if an avian influenza pandemic was officially declared. It contains hemagglutinin and neuraminidase surface antigens purified from inactivated viruses.
Dosage, time between each vaccine and side effects
Two doses of the H5N1 virus that causes avian influenza are being developed by pharmaceutical companies CSL Sekirus, one of the world’s largest vaccine manufacturers.Both are available as an injectable suspension 7.5 mcg per 0.5 ml dose.
this two doses Inclipan vaccine to be used in case of bird flu pandemic three weeks interval. They are suitable for adults and children over six months. In minors and adults, the vaccine will produce an immune response three weeks after two doses.
Regarding side effects, for adults, the most common is lower back pain, according to the EMA. Injection site, fatigue, headache, general malaise, myalgia and arthralgia. By itself, in minors 6 to 18 years of age, it may cause injection site pain, myalgia, fatigue, general malaise, headache, loss of appetite, nausea, and joint pain. Meanwhile, among children aged 0 to 6 years, injection site sensitivity, irritability, drowsiness, changes in eating habits and fever were most common.
.